

Supplementary Table S1: Multiple logistic regression, variables that influence the reach of target undetected viemia. The model correctness was verified with Hosmer-Lemeshow test (value 5.6, p=0.6898).

Variables	Odds ratio	95% CI
Zenith viremia cp/ml	1.000	1.000 to 1.000
CD4 nadir count, cell/mm ³	1.000	0.9988 to 1.002
Years on BIC-STR	1.643	1.038 to 2.660
Age	0.9837	0.9511 to 1.016

CI, confidence interval.

Supplementary Table S2: Multiple logistic regression, variables that influence a good immunological recovery, defined as CD4+ T cell count > 500 cells/mm³ in overall population. The model correctness was verified with Hosmer-Lemeshow test (value 8.6, p=0.3802).

Variables		Odds ratio	95% CI
Previous regimen	TAF-based	2.642	1.235 to 5.787
Zenith viremia, cp/ml		1.000	1.000 to 1.000
CD4 nadir, cells/mm ³		1.006	1.004 to 1.009
OI		0.7488	0.3035 to 1.838
HCV co-infection		0.6101	0.2232 to 1.649
Years on BIC-STR		0.9008	0.5911 to 1.364
Age		0.9872	0.9562 to 1.019


TAF, Tenofovir Alafenamide; OI, previous opportunistic infection; CI, confidence interval;

Supplementary Table S3: Multiple logistic regression, variables that influence a good immunological recovery, defined as CD4 count > 500 cell/mm³ patients aged over 60 years old. The model correctness was verified with Hosmer-Lemeshow test (value 8.7, p=0.3668).

Variables			Odds ratio	95% CI
Previous regimen	TAF-based		1.365	0.3032 to 6.080
Zenith viremia, cp/ml			1.000	1.000 to 1.000
CD4 nadir count, cells/mm ³			1.003	0.9982 to 1.008
Age			0.7879	0.6372 to 0.9386
OI			0.1378	0.01913 to 0.7464

TAF, Tenofovir Alafenamide; CI, confidence interval; OI, previous opportunistic infection

Causes of BIC-STR interruption



Supplementary Figure S1: Causes of bictegrovir/tenofovir alafenamide/emtricitabine interruption in 44 cases, expressed as percentage of total. *Dual-th, dual therapy.*